评估阿尔茨海默病生物标志物与临床终点之间的关系的统计框架
T Chen1, R M Hutchison, C Rubel
1Tianle Chen, Biogen Inc., 225 Binney St., Cambridge, MA 02142, Email address: tianle.chen@biogen.com, Phone: 617-914-7278.
The journal of prevention of Alzheimer's disease
|October 1, 2024
概括
本综述提出了一个统计框架,以标准化对阿尔茨海默病 (AD) 生物标志物的分析及其与治疗试验中的临床结果的联系. 协调这些评估将提高数据的可比性,促进AD治疗的发展.
科学领域:
- 神经学和临床试验研究
- 神经退行性疾病中的生物标志物分析.
背景情况:
- 阿尔茨海默病 (AD) 生物标志物反映了大脑变化和治疗效果,但它们与临床终点的关系需要标准化评估.
- 不一致的评估方法阻碍了在临床试验中解释抗粉样蛋白β (Aβ) 治疗效果.
研究的目的:
- 引入一个统计框架来评估治疗对早期和晚期AD生物标志物的影响.
- 评估AD生物标志物和临床终点之间的关系,无论是在主体和小组层面.
主要方法:
- 使用粉样PET,血p-tau和tau PET对比早期和晚期进展生物标志物的示例案例.
- 主体级相关性:生物标志物的基线变化与临床终点的基线变化相比.
- 组级相关性:与安慰剂调整的治疗对随机试验中的生物标志物和临床终点的影响.
主要成果:
- 对个体级别的相关性解释取决于特定的生物标志物和疾病阶段.
- 组级相关性利用随机对照试验来评估临床益处的生物标志物的预测性.
结论:
- 统一统计框架对于对AD生物标志物治疗效应及其临床相关性的一致评估至关重要.
- 标准化方法将在试验中产生可比的数据,可能为AD治疗揭示新的见解.
相关概念视频
01:26Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170